Devyser publishes annual report for 2023

Devyser´s annual report 2023 has today been published on the company´s website. 
 
The report is available on: https://investors.devyser.com/en/reports-presentations 
 
The financial year covers the period from 1 January to 31 December 2023. 

For more information, please contact:
Fredrik Alpsten, CEO 
Email: fredrik.alpsten@devyser.com 
Telephone: +46 70 667 31 06
 
Sabina Berlin, CFO 
Email: sabina.berlin@devyser.com 
Telephone: +46 739 51 95 02

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.